Core Viewpoint - The article highlights the advancements and projects of Kasei (Taiyuan) Biomaterials Co., Ltd., particularly in the production of bio-based materials, showcasing significant growth in revenue and profit, as well as innovative product applications in the industry [2][5]. Group 1: Project Developments - Kasei is constructing a project with an annual capacity of 500,000 tons of bio-based hexamethylenediamine and 900,000 tons of bio-based polyamide, located in the Shanxi Synthetic Biology Industrial Ecological Park [2]. - The company currently has a series of bio-based dicarboxylic acids (DC10-DC18) with an annual capacity of 115,000 tons, and a bio-based sebacic acid project with an annual capacity of 40,000 tons that commenced production in 2022 [4]. - The bio-based hexamethylenediamine has an annual capacity of 50,000 tons, primarily used as a raw material for bio-based polyamide production [4]. Group 2: Financial Performance - In the first half of 2025, Kasei achieved a revenue of 1.671 billion yuan, representing a year-on-year increase of 15.68% [5]. - The net profit attributable to shareholders reached 309 million yuan, up 24.74% year-on-year, while the net profit after deducting non-recurring items was 296 million yuan, reflecting a growth of 23.67% [5]. Group 3: Research and Development - The company invested 123.2 million yuan in R&D in the first half of 2025, a 23.13% increase year-on-year, accounting for 7.37% of its revenue [4]. - Significant progress has been made in R&D projects related to green dicarboxylic acids, bio-based piperidine, bio-based long-chain polyamides, and high-value utilization of agricultural waste [4].